AtriCure, Inc. will be participating in the UBS Global Healthcare Conference on November 12, 2024. During the conference, the company's management will provide insights into their innovative technologies and strategies for addressing health challenges.

AtriCure's Innovative Technologies

AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions. Their technologies aim to reduce complications associated with Afib and improve patient outcomes.

Notable Products

• The Isolator® Synergy™ Ablation System: the first FDA-approved medical device for treating persistent Afib.
• The AtriClip® Left Atrial Appendage Exclusion System: the most widely sold LAA management device globally.

Hybrid AF™ Therapy

AtriCure's Hybrid AF™ Therapy offers minimally invasive procedures for long-standing persistent Afib patients.

cryoICE cryoSPHERE® Probes

AtriCure also provides cryoICE cryoSPHERE® probes for temporary ablation of peripheral nerves, enhancing patient comfort and surgical outcomes.

Engaging with Investors and Stakeholders

By participating in the UBS Global Healthcare Conference, AtriCure aims to engage with investors and stakeholders, highlighting its strategic initiatives and the impact of its technologies on patient care. The fireside chat format fosters a deeper connection with the audience and encourages dialogue. AtriCure's proactive approach to investor relations reflects its commitment to transparency and building trust within the investment community.

A Leader in Surgical Treatment

With its innovative technologies and focus on patient outcomes, AtriCure is positioned as a leader in the surgical treatment of atrial fibrillation and related conditions.